168 related articles for article (PubMed ID: 38664770)
1. Octamer-binding transcription factor 4-positive circulating tumor cell predicts worse treatment response and survival in advanced cholangiocarcinoma patients who receive immune checkpoint inhibitors treatment.
Pei F; Tao Z; Lu Q; Fang T; Peng S
World J Surg Oncol; 2024 Apr; 22(1):110. PubMed ID: 38664770
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumor cells are associated with poor overall survival in patients with cholangiocarcinoma.
Yang JD; Campion MB; Liu MC; Chaiteerakij R; Giama NH; Ahmed Mohammed H; Zhang X; Hu C; Campion VL; Jen J; Venkatesh SK; Halling KC; Kipp BR; Roberts LR
Hepatology; 2016 Jan; 63(1):148-58. PubMed ID: 26096702
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal change of circulating tumour cell count and its relation to prognosis in advanced intrahepatic cholangiocarcinoma patients.
Jiang S; Tang W; Huang B
Scand J Clin Lab Invest; 2023 Jul; 83(4):234-240. PubMed ID: 37199131
[TBL] [Abstract][Full Text] [Related]
4. Preoperative C-reactive protein-to-albumin ratio predicts long-term outcomes in extrahepatic cholangiocarcinoma patients.
Yasukawa K; Shimizu A; Motoyama H; Kubota K; Notake T; Fukushima K; Ikehara T; Hayashi H; Kobayashi A; Soejima Y
J Surg Oncol; 2020 Nov; 122(6):1094-1105. PubMed ID: 32634266
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal change of circulating tumor cell level and its relationship with immune checkpoint inhibitor-based treatment benefits in unresectable, metastatic colorectal cancer patients.
Fan H; Bai L; Bai K
Scand J Clin Lab Invest; 2023 Jul; 83(4):227-233. PubMed ID: 37247200
[TBL] [Abstract][Full Text] [Related]
6. OCT4‑positive circulating tumor cells may predict a poor prognosis in patients with metastatic castration‑resistant prostate cancer treated with abiraterone plus prednisone therapy.
Ma Y
Oncol Lett; 2023 Oct; 26(4):452. PubMed ID: 37720669
[TBL] [Abstract][Full Text] [Related]
7. The Upregulation of OCT4 in Acidic Extracellular pH is Associated with Gemcitabine Resistance in Cholangiocarcinoma Cell Lines.
Choodetwattana P; Proungvitaya S; Jearanaikoon P; Limpaiboon T
Asian Pac J Cancer Prev; 2019 Sep; 20(9):2745-2748. PubMed ID: 31554372
[TBL] [Abstract][Full Text] [Related]
8. The prognostic role of lymphovascular invasion and lymph node metastasis in perihilar and intrahepatic cholangiocarcinoma.
Lurje G; Bednarsch J; Czigany Z; Lurje I; Schlebusch IK; Boecker J; Meister FA; Tacke F; Roderburg C; Den Dulk M; Gaisa NT; Bruners P; Neumann UP
Eur J Surg Oncol; 2019 Aug; 45(8):1468-1478. PubMed ID: 31053477
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.
Ouyang Y; Liu W; Zhang N; Yang X; Li J; Long S
Cancer Med; 2021 Oct; 10(20):7021-7039. PubMed ID: 34423578
[TBL] [Abstract][Full Text] [Related]
10. High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin.
Huh G; Ryu JK; Chun JW; Kim JS; Park N; Cho IR; Paik WH; Lee SH; Kim YT
BMC Cancer; 2020 Sep; 20(1):907. PubMed ID: 32967632
[TBL] [Abstract][Full Text] [Related]
11. The Prognostic Role of SOCS3 and A20 in Human Cholangiocarcinoma.
Wang Y; Wan M; Zhou Q; Wang H; Wang Z; Zhong X; Zhang L; Tai S; Cui Y
PLoS One; 2015; 10(10):e0141165. PubMed ID: 26485275
[TBL] [Abstract][Full Text] [Related]
12. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
13. Circulating Biomarkers for Cholangiocarcinoma.
Loosen SH; Vucur M; Trautwein C; Roderburg C; Luedde T
Dig Dis; 2018; 36(4):281-288. PubMed ID: 29807369
[TBL] [Abstract][Full Text] [Related]
14. Circulating miR-106a is a Novel Prognostic and Lymph Node Metastasis Indicator for Cholangiocarcinoma.
Cheng Q; Feng F; Zhu L; Zheng Y; Luo X; Liu C; Yi B; Jiang X
Sci Rep; 2015 Nov; 5():16103. PubMed ID: 26534789
[TBL] [Abstract][Full Text] [Related]
15. Impact of the Preoperative C-reactive Protein to Albumin Ratio on the Long-Term Outcomes of Hepatic Resection for Intrahepatic Cholangiocarcinoma.
Ito T; Shinkawa H; Takemura S; Tanaka S; Nishioka T; Miyazaki T; Ishihara A; Kubo S
Asian Pac J Cancer Prev; 2020 Aug; 21(8):2373-2379. PubMed ID: 32856868
[TBL] [Abstract][Full Text] [Related]
16. Serum KIAA1199 is an advanced-stage prognostic biomarker and metastatic oncogene in cholangiocarcinoma.
Zhai X; Wang W; Ma Y; Zeng Y; Dou D; Fan H; Song J; Yu X; Xin D; Du G; Jiang Z; Zhang H; Zhang X; Jin B
Aging (Albany NY); 2020 Nov; 12(23):23761-23777. PubMed ID: 33197891
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Impact of the Initial Postoperative CA19-9 Level in Patients with Extrahepatic Bile Duct Cancer.
Kato Y; Takahashi S; Gotohda N; Konishi M
J Gastrointest Surg; 2016 Aug; 20(8):1435-43. PubMed ID: 27250990
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of immune checkpoint inhibitors in unresectable or metastatic combined hepatocellular-cholangiocarcinoma.
Jang YJ; Kim EJ; Kim HD; Kim KP; Ryu MH; Park SR; Choi WM; Lee D; Choi J; Shim JH; Kim KM; Lim YS; Lee HC; Ryoo BY; Yoo C
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7547-7555. PubMed ID: 36971796
[TBL] [Abstract][Full Text] [Related]
19. An Increased Chromosome 7 Copy Number in Endoscopic Bile Duct Biopsy Specimens Is Predictive of a Poor Prognosis in Cholangiocarcinoma.
Kato A; Naitoh I; Miyabe K; Hayashi K; Yoshida M; Hori Y; Natsume M; Jinno N; Asano G; Kato H; Kuno T; Takahashi S; Kataoka H
Dig Dis Sci; 2018 Dec; 63(12):3376-3381. PubMed ID: 30206756
[TBL] [Abstract][Full Text] [Related]
20. First-line PD-1 inhibitors combination therapy for patients with advanced cholangiocarcinoma: A retrospective real-world study.
Ye Z; Zhang Y; Chen J; Wang X; Hong Y; Zhao Q
Int Immunopharmacol; 2023 Jul; 120():110344. PubMed ID: 37245298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]